AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyPhase 3Trial registry record – peer review not applicable
Research on Ocrelizumab in Human Participants with Multiple Sclerosis
This Phase 3 interventional study aimed to enroll approximately 500 participants to evaluate changes in physical functioning over up to 5 years for those receiving Ocrelizumab. However, no results are currently posted, and planned enrolment and endpoints do not constitute findings.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a trial registry record and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- No results yet
- Outcome
- Not reported
Why it matters
Understanding the effects of Ocrelizumab on physical functioning in Multiple Sclerosis could inform treatment strategies and patient outcomes.
What this does not prove
The absence of results means conclusions cannot be drawn, and the planned enrolment does not provide evidence of efficacy or safety.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- 500 · estimated
- Randomised
- Not applicable
- Controlled
- No
- Primary endpoint met
- Not reported
- Relevant MS type
- All
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
Supporting passages (16)
study phasePhase: Phase 3
study designStudy type: Interventional
subjectsParticipants: people; ages from 18 Years; sex All
speciesParticipants: people; ages from 18 Years; sex All
sample sizeEnrollment: 500 participants (estimated)
sample size basisEnrollment: 500 participants (estimated)
peer reviewedPublication date: unknown.
relevant ms typesConditions: Multiple Sclerosis
interventionInterventions: Ocrelizumab
findingsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
limitationsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
peer reviewedTrial registry record.
randomizedAllocation: Not applicable
controlledIntervention model: Single group
primary endpointPrimary endpoints: Change From Baseline to End of Study in the Physical Functioning Score of the Patient-Reported Outcome Measure Information System/Quality of Life in Neurological Disorders - Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a); Number of Eligible Participants who Have Received Access to Ocrelizumab in the Study
follow upFollow-up: Baseline up to 5 years; Up to 5 years
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.